Parabens are a widely used made made preservative, popularly Butylparaben (BP) . They are also a xenoestrogen, which is a synthetic compound that behaves like estrogen by binding to and activating estrogen receptors. Exposure to estrogens and xenoestrogens has been linked to breast cancer.
However, the current stance held by the FDA is that previous studies have concluded that the low doses of parabens exposure in today’s products is safe enough. Over the decades parabens have been a focus of scrutiny. In the 1990s studies like that conducted began detecting the estrogenic ability of parabens. They labeled parabens a form of xenoestrogen, which is a type of hormone that mimics estrogen which can lead to reproductive disorders and certain types of cancer.
Later, in 2004 Philippa Darbre, Ph.D found parabens present in malignant breast tumors. The counter to this study was that Darbe failed to examine if parabens were present in non-cancerous breast tissues. Also, the presence of parabens in breast tissue doesn’t necessarily prove that parabens caused the cancer. From this study, the prevailing paradigm remained that parabens proved only to have weak estrogenic effects, which in small enough doses are deemed to be safe.
However, later studies proved that parabens had the ability to bioaccumulate. This would make parabens more dangerous if they are able to compound? Secondly, a new study found that chemicals or compounds in the human body that are not present in the isolated petri dish experiments that could enhance or speed up the effects of parabens.
In this article we will take a look new studies that are challenging the notion that parabens are safe to use in small doses.